The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
 
Collin M. Blakely
Consulting or Advisory Role - Amgen; Bayer; Blueprint Medicines; Foundation Medicine; OncoCyte
Research Funding - AstraZeneca (Inst); Ignyta (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
 
Matthew A. Gubens
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Inivata; Sanofi/Regeneron; Takeda
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst); Trizell (Inst)
 
Gregory M. Allen
No Relationships to Disclose
 
Shrusti Shah
No Relationships to Disclose
 
Matthew Jereza
No Relationships to Disclose
 
Bianca Bacaltos
No Relationships to Disclose
 
Sourav Bandyopadhyay
No Relationships to Disclose